Dymicron Launches Regulation A+ Equity Crowdfunding Investment Offering

Company Seeks $15.8 million for FDA trial and international expansion with Triadyme®-C cervical total disc replacement

Dymicron today announced that it is launching an offering of securities through the use of an offering statement that has been qualified by the Securities and Exchange Commission.

Dymicron has partnered with DealMaker for its self-hosted $15.8 million raise. Regulation A+ raise. Regulation A+ is a relatively new exemption which allows private companies to sell their shares to unaccredited investors. “Medical Device companies have recently found this approach to fundraising attractive to investors and we are proud to be one of the leaders in the medical device industry to be on the forefront of this movement to democratize the capital fundraising process” said Alan Layton Chairman and CEO.

About Triadyme® – C
The Triadyme-C is a motion preserving cervical artificial disc made of polycrystalline diamond, one of the most robust and durable materials known to mankind. As a result, the Tri­adyme-C produces virtually no detectable wear, minimizing the risk of any wear debris-related complications, ensuring performance for the lifetime of the patient. The Triadyme-C’s patented Tri-Lobe design mimics the natural kinematics and motion of a normal disc.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

MMI notes the funds will support commercialization of the Symani® Surgical System in high-growth markets and continued investment in studies that generate clinical evidence and enable indication expansion. Investments will also accelerate advanced technology capabilities and enable MMI to scale its operational capabilities globally.
“We are excited to begin our journey as a public company with this additional investment. We believe Tevogen’s patient-centric approach, which merges a focus on affordability with advanced science, is a blueprint for sustainable success in the current era of healthcare. I am pleased that investors now have the opportunity to participate in Tevogen’s mission to become the very first life science company offering commercially attractive and affordable personalized T cell therapies for large patient populations in virology, oncology, and neurology, said the CEO of Tevogen Bio.
MB2 Dental notes the financing will be used to fund upcoming acquisitions and future growth for the company, following a record year of growth in 2023 with 150 new partnerships.
Procyrion notes the funding will support the DRAIN-HF pivotal IDE trial evaluating the company's Aortix pump, internal R&D programs to improve manufacturability, and commercialization preparation.
PhotoniCare, in January of this year, announced that the U.S. Food and Drug Administration had granted clearance for its TOMi™ Scope for non-invasive imaging of the middle ear.

By using this website you agree to accept Medical Device News Magazine Privacy Policy